Multiple Myeloma Clinical Trials in Winston-Salem, North Carolina

10 studies are recruiting for multiple myeloma in Winston-Salem, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Wake Forest Baptist Health /ID# 271294, Winston-Salem, North Carolina

   Locations

   50 in total

   Run by

   AbbVie

   See if you can join NCT06953960 on ClinicalTrials.gov

2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

   The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-C…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem, North Carolina

   Locations

   75 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07555938 on ClinicalTrials.gov

3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Novant Health Forsyth Medical Center, Winston-Salem, North Carolina

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

4. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

   Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Atrium Health Wake Forest Baptist Medical Center /ID# 274847, Winston-Salem, North Carolina

   Locations

   34 in total

   Run by

   AbbVie

   See if you can join NCT06892522 on ClinicalTrials.gov

5. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

   Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Atrium Health Wake Forest Baptist Medical Center /ID# 251165, Winston-Salem, North Carolina

   Locations

   46 in total

   Run by

   AbbVie

   See if you can join NCT05650632 on ClinicalTrials.gov

6. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

   This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Wake Forest University Health Sciences, Winston-Salem, North Carolina

   Locations

   42 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT05137054 on ClinicalTrials.gov

7. A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

   The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   GSK Investigational Site, Winston-Salem, North Carolina

   Locations

   181 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06679101 on ClinicalTrials.gov

8. The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

   To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.

   Stage

   Not phased

   Ages

   18 to 120

   Site

   Wake Forest Baptist Health, Winston-Salem, North Carolina

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT01890486 on ClinicalTrials.gov

9. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

   A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Atrium Wake Forest Baptist Medical Center, Winston-Salem, North Carolina

   Locations

   104 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04988555 on ClinicalTrials.gov

10. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

    This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina

    Locations

    12 in total

    Run by

    Indapta Therapeutics, INC.

    See if you can join NCT06119685 on ClinicalTrials.gov